Human Pluripotent Stem Cell Differentiation for Insulin Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to develop in vitro methods to generate functional insulin-expressing cells that more closely resemble β cells, as existing methods from mouse embryonic stem cells may not accurately mimic human pancreatic development.
Innovation Solution
A method to differentiate human pluripotent stem cells into cells expressing markers characteristic of the pancreatic endocrine lineage that co-express NKX6.1 and insulin and minimal amounts of glucagon, involving culturing and treating the cells with a protein kinase C activator.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mouse embryonic stem cells are used to generate insulin-secreting structures, then insulin-producing cells can be obtained, but the cells do not accurately mimic human pancreatic development
Solution Approach 1:
The patent applies parameter changes by modifying the differentiation protocol parameters - specifically using retinoic acid treatment at defined concentrations and durations, combined with growth factor combinations (FGF2, FGF10, Activin A, BMP4) at optimized dosages. These parameter adjustments transform the differentiation process to generate human-like β cells with proper marker expression (PDX1, NKX6.1, INS) and reduced glucagon co-expression, thereby improving reliability while maintaining adaptability for human therapy
2Manufacturing precision
If pluripotent stem cells are differentiated into pancreatic endocrine lineage, then insulin-expressing cells are produced, but the cells co-express glucagon which reduces their β-cell purity
Solution Approach 1:
The patent employs parameter changes by precisely controlling the differentiation timeline and growth factor dosages. Retinoic acid is added at specific concentrations (0.1-10 μM) at defined time points during differentiation, and growth factors are administered in optimized combinations and durations. These parameter optimizations enhance β-cell purity by suppressing glucagon co-expression while maintaining insulin production, thereby improving manufacturing precision without sacrificing productivity
Solution Approach 2:
The patent uses retinoic acid as an intermediary substance that mediates the differentiation process. Retinoic acid acts as a signaling molecule that guides pluripotent stem cells through specific differentiation pathways toward the pancreatic endocrine lineage while suppressing alternative lineages. This intermediary mechanism enables precise control over cell fate decisions, achieving high purity insulin-expressing cells with minimal glucagon co-expression
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method efficiently produces cells that express NKX6.1 and insulin, resembling human β cells, with potential for treating Type I diabetes through cell-replacement therapy.
Implementation Method 1
treating the cells expressing markers characteristic of the pancreatic endoderm lineage with medium supplemented with a protein kinase C activator
Data Source
AI summary
The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells expressing markers characteristic of the pancreatic endocrine lineage that co-express NKX6.1 and insulin and minimal amounts of glucagon.